CEPI partners with Bharat Biotech, Unversity of Sydney and ExcellGene to develop variant proof Covid-19 vaccine
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium